Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) is a proglucagon‐derived peptide secreted from gut endocrine cells in response to nutrient ingestion. The multifaceted actions of GLP‐1 include the following: (1) the stimulation of insulin secretion and of its gene expression, (2) the inhibition of glucagon secretion, (3) the inhibition of food intake, (4) the proliferation and differentiation of beta cells, and (5) the protection of beta‐cells from apoptosis. The therapeutic utility of the native GLP‐1 molecule is limited by its rapid enzymatic degradation by a serine protease termed dipeptidyl peptidase‐IV (DPP‐IV). The present article reviews the research studies aimed at elucidating the biosynthesis, metabolism, and molecular characteristics of GLP‐1 since it is from these studies that the development of a GLP‐1‐like pharmacological agent may be derived. Copyright © 2005 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Self-citationHamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649 · cited 1×
“The preproglucagon gene was cloned by two independent groups in the mideighties [1,2].”
MethodThe Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 1×
“The multifaceted physiological actions of GLP-1 include stimulation of insulin gene expression, stimulation of insulin secretion, trophic effects on the beta-cells, inhibition of glucagon secretion, promotion of satiety, inhibition of food intake, and the reduction of gastric emptying, all of which contribute to norma…”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 2×
“1[7–36 amide] and GLP-1 [7–37] have been shown to”
BackgroundSelf-citationDegn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · cited 2×
“Chang et al have reported that NN2211 restored beta-cell responsiveness to physiological hyperglycemia in type 2 diabetic subjects [123], and Degn et al reported that a one-week treatment with a single daily dose of the NN2211 improved the glycemic control throughout 24 h of daily living [124].”
BackgroundAhrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300 · cited 1×
“These results were similar to those obtained by using a buffer solution containing DPP-IV [144], suggesting that metformin might act as a DPP-IVDPP-IV inhibitor.”
Result
Cited by
The role of medicinal plants in the treatment of diabetes: a systematic review
Kooti, W., Farokhipour, M., Asadzadeh, Z., Ashtary-Larky, D., & Asadi-Samani, M. (2016) · Electronic physician · doi:10.19082/1832 · Cited by 460
Liu, Z., & Habener, J. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706105200 · Cited by 326
Glucagon-like peptide-1 analogues: An overview
Gupta, V. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111625 · Cited by 186
Wu, X., Li, S., Xue, P., & Li, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.018 · Cited by 92
“GLP-1 induces multiple signaling pathways through activation of the pleiotropic GLP-1R, including classical cAMP/PKA pathway and other second messengers [25-29].”
BackgroundCheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
Metadata
- Authors
- Hui, H., Zhao, X., & Perfetti, R.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2005-04-26
- Volume
- 21
- Issue
- 4
- Pages
- 313-331
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2109517949
- Cited by
- 97
- References
- 14
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes. https://app.cochat.ai/papers/10.1002/dmrr.553
- The paper
- Hui, H., Zhao, X., & Perfetti, R. (2005). Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.